Elisabeth Buchdunger

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. doi request reprint Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis
    Carola Leipner
    Institute of Virology, Medical Faculty, Friedrich Schiller University, Jena, Germany
    Cardiovasc Res 79:118-26. 2008
  2. ncbi request reprint [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia]
    Elisabeth Buchdunger
    Präklinische Forschung Onkologie, Novartis Pharma AG, Basel, Schweiz
    Med Klin (Munich) 97:2-6. 2002
  3. ncbi request reprint Pharmacology of imatinib (STI571)
    Elisabeth Buchdunger
    Oncology Research Department, Novartis Pharma AG, CH 4002 Basel, Switzerland
    Eur J Cancer 38:S28-36. 2002
  4. ncbi request reprint Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
    Renaud Capdeville
    Novartis Pharma AG, S 27 2 033, CH 4002 Basel, Switzerland
    Nat Rev Drug Discov 1:493-502. 2002
  5. ncbi request reprint Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
    Doriano Fabbro
    Department of Oncology, Novartis Pharma Inc, WKL 125 4 10, CH 4002, Basel, Switzerland
    Pharmacol Ther 93:79-98. 2002
  6. ncbi request reprint Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro
    Peter J Houghton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer Res 64:2333-7. 2004
  7. ncbi request reprint Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
    Yiguo Hu
    The Jackson Laboratory, 600 Main St, Bar Harbor, Maine 04609, USA
    Nat Genet 36:453-61. 2004
  8. ncbi request reprint The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling
    G Sakuntala Warshamana-Greene
    Department of Medicine, Virginia Commonwealth University and McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249, USA
    Mol Cancer Ther 3:527-35. 2004
  9. ncbi request reprint The development of imatinib as a therapeutic agent for chronic myeloid leukemia
    Michael Deininger
    Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, Mailcode L592, Portland, OR 97239, USA
    Blood 105:2640-53. 2005
  10. ncbi request reprint The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy
    G Sakuntala Warshamana-Greene
    Department of Medicine, Virginia Commonwealth University and McGuire Veterans Affairs Medical Center, Richmond, VA 23249, USA
    Clin Cancer Res 11:1563-71. 2005

Collaborators

Detail Information

Publications17

  1. doi request reprint Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis
    Carola Leipner
    Institute of Virology, Medical Faculty, Friedrich Schiller University, Jena, Germany
    Cardiovasc Res 79:118-26. 2008
    ..To test if PDGF stimulation of resident fibroblasts causally contributes to fibrosis, we employed inhibition of PDGF receptor signalling with the orally available kinase inhibitor Imatinib...
  2. ncbi request reprint [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia]
    Elisabeth Buchdunger
    Präklinische Forschung Onkologie, Novartis Pharma AG, Basel, Schweiz
    Med Klin (Munich) 97:2-6. 2002
    ..Recent studies with clinical samples from resistant patients have shown that point mutations in the kinase domain of Bcr-Abl play a role in the development of resistance to STI571...
  3. ncbi request reprint Pharmacology of imatinib (STI571)
    Elisabeth Buchdunger
    Oncology Research Department, Novartis Pharma AG, CH 4002 Basel, Switzerland
    Eur J Cancer 38:S28-36. 2002
    ..The pharmacology of imatinib and its activity in various tumor models is discussed...
  4. ncbi request reprint Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
    Renaud Capdeville
    Novartis Pharma AG, S 27 2 033, CH 4002 Basel, Switzerland
    Nat Rev Drug Discov 1:493-502. 2002
    ..Here, we describe how this programme led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer...
  5. ncbi request reprint Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
    Doriano Fabbro
    Department of Oncology, Novartis Pharma Inc, WKL 125 4 10, CH 4002, Basel, Switzerland
    Pharmacol Ther 93:79-98. 2002
    ..Phase I/II studies demonstrated that STI571 is well tolerated, and that it showed promising hematological and cytogenetic responses in CML and clinical responses in the c-Kit-driven gastrointestinal tumors...
  6. ncbi request reprint Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro
    Peter J Houghton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer Res 64:2333-7. 2004
    ..These results suggest that imatinib mesylate inhibits the function of ABCG2 but is not a substrate for this transporter...
  7. ncbi request reprint Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
    Yiguo Hu
    The Jackson Laboratory, 600 Main St, Bar Harbor, Maine 04609, USA
    Nat Genet 36:453-61. 2004
    ..These results implicate Src family kinases as therapeutic targets in Ph(+) B-ALL and suggest that simultaneous inhibition of Src and Bcr-Abl kinases may benefit individuals with Ph(+) acute leukemia...
  8. ncbi request reprint The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling
    G Sakuntala Warshamana-Greene
    Department of Medicine, Virginia Commonwealth University and McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249, USA
    Mol Cancer Ther 3:527-35. 2004
    ..These observations suggest that, in tumors in which critical signal transduction pathways can be activated by alternative receptors, optimal therapy may require inhibition of multiple receptors...
  9. ncbi request reprint The development of imatinib as a therapeutic agent for chronic myeloid leukemia
    Michael Deininger
    Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, Mailcode L592, Portland, OR 97239, USA
    Blood 105:2640-53. 2005
    ..In this manuscript, we review the preclinical and clinical development of imatinib for the therapy of CML, resistance and strategies that may help to eliminate resistant or residual leukemia...
  10. ncbi request reprint The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy
    G Sakuntala Warshamana-Greene
    Department of Medicine, Virginia Commonwealth University and McGuire Veterans Affairs Medical Center, Richmond, VA 23249, USA
    Clin Cancer Res 11:1563-71. 2005
    ..The purpose of this study was to determine whether the novel IGF-I receptor (IGF-IR) kinase inhibitor, NVP-ADW742, sensitizes SCLC cell lines to etoposide and carboplatin, which are commonly used in the treatment of SCLC...
  11. ncbi request reprint Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits
    Olli Leppanen
    Ludwig Institute for Cancer Research, Uppsala, Sweden
    Circulation 109:1140-6. 2004
    ....
  12. ncbi request reprint STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake
    Kristian Pietras
    Ludwig Institute for Cancer Research, SE 751 24 Uppsala, Sweden
    Clin Cancer Res 9:3779-87. 2003
    ....
  13. ncbi request reprint Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits
    Roope K Sihvola
    Cardiopulmonary Research Group, Transplantation Laboratory, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Transplantation 75:334-9. 2003
    ..In this study, we tested the effect of STI 571, a novel orally active protein tyrosine kinase (PTK) inhibitor selective for PDGF receptor (PDGF-R) on transplant and accelerated arteriosclerosis in hypercholesterolemic rabbits...
  14. ncbi request reprint Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia
    John M L Ebos
    Molecular and Cell Biology Research, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada M4N 3M5
    Mol Cancer Res 1:89-95. 2002
    ..Taken together, our results implicate BCR-ABL as a possible regulator of CML angiogenesis and raise the possibility that STI-571 could mediate some of its anti-CML properties in vivo through an angiogenesis-dependent mechanism...
  15. ncbi request reprint Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases
    Markus Warmuth
    Klinische Kooperationsgruppe für Gentherapie, GSF Forschungszentrum für Umwelt und Gesundheit, Munich, Germany
    Blood 101:664-72. 2003
    ..The results suggest that the use of Src kinase inhibitors is a potential strategy to prevent or overcome clonal evolution of imatinib mesylate resistance in Bcr-Abl(+) leukemia...
  16. ncbi request reprint Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy
    Kristian Pietras
    Ludwig Institute for Cancer Research, SE 751 24 Uppsala, Sweden
    Cancer Res 62:5476-84. 2002
    ..In conclusion, our study identifies inhibition of PDGF signaling in tumor stroma as a novel, possibly general strategy for enhancement of the therapeutic effects chemotherapy...
  17. ncbi request reprint Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571
    Amie S Corbin
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97201, USA
    J Biol Chem 277:32214-9. 2002
    ....